Navigation Links
Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025
Date:5/4/2010

NEW YORK, May 4 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Pain Relieving Drug Market Analysis 2010-2025

http://www.reportlinker.com/p0191843/Global-Pain-Relieving-Drug-Market-Analysis-2010-2025.html

Reports details

– where will opportunities lie in this diverse market with high, growing demand worldwide?

In 2009, the global pain relieving drug market generated revenues over $50bn. From 2010, that sector will benefit from new drugs and reformulations of existing products. Cases of pain from many conditions are increasing rapidly. Worldwide, the treatment of pain is a priority for healthcare providers, with high demand for drugs. Where is the pain relieving drug market heading - technologically and commercially - from 2010 onwards? 

Our new report - Global Pain Relieving Drug Market Analysis 2010-2025 - explains how this market will develop, and where the opportunities will lie. We show how you can benefit from its developments and potential. There remains unmet therapeutic needs in the treatment of pain. Many conditions have no pain relievers designed for relieving their symptoms, or very few. Side effects and safety constitute a challenge for drug developers. There is also increasing demand for pain treatments in developing countries. Novel compounds that show improved safety – with high efficacy – can gain significant market shares from 2010 onwards. There remain high revenues to be made in this sector from 2010 to 2025, our new report explains how you can benefit from this opportunity.

Global Pain Relieving Drug Market 2010-2025 covers the following therapeutic categories:

• Narcotics for pain

• NSAIDs for pain

• Treatments for arthritic pain

• Treatments for migraine

• Treatments for neuropathic pain

• Local anaesthetics.

What types of therapeutic agents are likely to enter the market from 2010 onwards, and will they dominate? Where do the main opportunities lie, and what are the drivers and restraints in this market? This report will provide you with the information that you need to understand current trends and future directions in the global pain drug market.

Comprehensive analysis of the global pain drug market

Global Pain Relieving Drug Market 2010-2025 examines that sector through a comprehensive review of information sources. We harness both primary and secondary research. This report provides unique sales forecasts, market share analyses, discussions of R&D pipeline developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are 75 tables and figures included, as well as two original interviews with experts which are unavailable elsewhere. The result is a comprehensive market- and industry-centered study, with detailed analyses and informed opinion to benefit your work.

Why you should buy Global Pain Relieving Drug Market 2010-2025

This report gives you the following benefits in particular:

• You will review the current market for pain-relieving drugs

• You will analyse the overall pain drug market, including a global sales forecast for 2010 to 2025

• You will receive sales forecasts for pain submarkets from 2010 to 2025, with discussions

• You will receive sales forecasts for leading products from 2010 to 2025, with discussions of market potential and competition

• You will receive sales forecasts for leading geographical markets from 2010 to 2025, with discussions

• You will discover prospects for leading companies from 2010 onwards

• You will analyse the drivers, restraints, competition and opportunities influencing the pain drug sector

• You will discover the most-exciting R&D pipeline developments

• You will discover expert views from our survey, including full interview transcripts

• You will investigate under-met needs, with therapeutic requirements and commercial opportunities covered.

You can obtain this report today

Nobody with an interest in the pain relieving drug industry and market should overlook our new study. We predict that total revenues will increase during our forecast period. Rising prevalence of the many conditions associated with pain - coupled with high social and economic costs of pain - are therapeutic and commercial drivers of this market. Do you want to harness those opportunities? You can stay ahead by ordering this report today.

Gain an understanding of how to tap into the potential of this market by ordering Global Pain Relieving Drug Market Analysis 2010-2025 today.

Table of Contents

1. Executive Summary

1.1 The Pain Relieving Drug Market: Entering a Crucial Period

1.2 Aims, Scope and Format of the Report

1.3 Research & Analysis Methods

2. Introduction to Pain and its Treatment

2.1 What is Pain?

2.1.1 Historical Aspects of Pain

2.2 Pain Pathways

2.2.1 WHO Pain Ladder

2.3 Classification and Types of Pain

2.3.1 Acute Pain

2.3.2 Chronic Pain

2.3.2.1 Psychosocial Effects of Chronic Pain

2.3.2.2 The Financial Burden of Chronic Pain

2.3.2.3 Chronic Cancer Pain

2.3.2.4 Breakthrough Cancer Pain

2.4 Neuropathic Pain

2.4.1 Distinguishing Neuropathic Pain

2.5 Neurochemistry of Pain

2.5.1 Prostaglandins

2.5.2 Opioids

2.6 Pain Treatments

2.7 OTC Pain Relievers

3. The Global Pain Pharmaceutical Market 2010-2025

3.1 The Global Pain Market: Analysis and Forecast

3.2 Sub-Market Categories of the Global Pain Drug Market

3.2.1 Oxycontin Currently Leads the Global Pain Drug Market

3.2.2 The Anti-Epileptics Segment: Will its Success Last?

3.3 Success in the Pain Relieving Drug Market Has Proved Challenging

3.4 While the Past Has Been Difficult for Pain Management, There is Optimism for the Future

4. The Global Narcotics Market 2010-2025

4.1 The Narcotics Market Analysis and Forecast

4.2 Oxycontin – Therapeutic and Commercial Challenges

4.2.1 Development of Oxycontin (Oxycodone)

4.3 Duragesic (Fentanyl) – Challenges in the Market

4.3.1 Development of Duragesic (Fentanyl)

4.4 Fentanyl MYLA Will Show Strong Revenues

4.4.1 Fentanyl

4.5 Actiq Fighting a Decline in Sales

4.5.1 Actiq (Fentanyl Citrate)

4.6 Other Agents

4.7 Total Sales in the Narcotics Market Will Increase, Despite its Being Crowded

5. The Global Non-Narcotics Market 2010-2025

5.1 The Non-Narcotics Market Analysis and Forecast

5.2 Efferalgan is Currently the Non-Narcotic Market's Leading Drug

5.2.1 Development of Efferalgan (Paracetamol/Acetaminophen)

5.3 Tylenol – a Future Blockbuster of the Non-Narcotics Market?

5.3.1 Development of Tylenol (Paracetamol/Acetaminophen)

5.4 Doliprane (Paracetamol/Acetaminophen)

5.5 Will Advil Exhibit Strong Growth?

5.5.1 Advil (Ibuprofen)

5.6 Aspirin Bayer – Line Extensions Keeping Sales Up

5.6.1 Aspirin Bayer (Acetylsalicylic Acid)

5.7 Other Agents

6. The Global Arthritic Pain Drug Market 2010-2025

6.1 The Arthritic Pain Market Analysis and Forecast

6.1.1 Safety Issues for COX-2 Inhibitors

6.2 Pfizer's Celebrex Dominates the Market, but Will it Last?

6.2.1 Development of Celebrex (Celecoxib)

6.3 Voltaren Will Exhibit Strong Growth

6.3.1 Development of Voltaren (Diclofenac)

6.4 Arcoxia: Strong Growth over the Forecast Period?

6.4.1 Development of Arcoxia (Etoricoxib)

6.5 Loxonin: Sales in Developing Countries Aiding Growth

6.5.1 Loxonin (Loxoprofen)

6.6 Mobic Will Suffer from Generic Competition

6.6.1 Development of Mobic (Meloxicam)

6.7 Other Agents

6.8 Outlook for the Arthritis Pain Drug Market

7. The Global Migraine Market 2010-2025

7.1 The Migraine Drug Market Analysis and Forecast

7.2 GSK's Blockbuster Imitrex/Imigran Faces Revenue Decline

7.2.1 Development of Imitrex/Imigran (Sumatriptan)

7.3 Maxalt's Patent Expiry Will Affect Sales

7.3.1 Development of Maxalt (Rizatriptan)

7.4 Zomig's Decline in Sales

7.4.1 Development of Zomig (Zolmitriptan)

7.5 Relpax Will Exhibit Loss of Revenue from 2010-2025

7.5.1 Development of Relpax (Eletriptan)

7.6 Other Agents

7.7 What Does the Future Hold for Migraine Therapy?

7.8 Unmet Needs in the Treatment of Migraine

8. Neuropathic Pain and Local Anaesthetics Markets 2010-2025

8.1 Introduction

8.1.1 Anti-Epileptic Drugs Market

8.2 Anti-Epileptic Market Analysis and Forecast

8.2.1 Lyrica

8.2.2 The Development of Lyrica (Pregabalin)

8.2.3 Topamax (Topiramate): Impending Patent Expiry

8.2.4 Topamax: Challenges this Product has to Face

8.2.5 Other Agents

8.3 Local Anaesthetic Market Analysis and Forecast

8.3.1 Lidoderm (Lidocaine) Forecast

8.3.2 Lidoderm: Market Leader for the Local Anaesthetic Market

8.3.3 Other Agents

9. SWOT Analysis of the Global Pain Drug Market

9.1 SWOT Analysis

9.2 Market Drivers

9.3 Market Restraints

9.4 The Pain Market Suffered After the Withdrawal of COX-2 Inhibitors

9.5 Lack of Adequate Reimbursement Limits Potential of Pain Drugs

9.6 Patients Dependent on Reformulations of Existing Drugs

9.7 The Narcotics Market Suffers from Side Effects

9.8 Risk of Intestinal Bleeding Associated with NSAIDs

9.9 The Under-Treatment of Pain

9.10 How Will Those Findings Affect Commercial Prospects?

9.11 The Future of the Pain Market – Closing Comments

9.11.1 Improved Use of New and Existing Pain Management Therapies

9.11.2 Analgesic Effects of Established Drugs for Other Indications

9.11.3 Personalised Pain Management Therapy?

10. Geographical Breakdown of the Global Pain Market 2010-2025

10.1 The Pain Drug Market: Regional Sales Breakdown

10.2 Countries Leading the Global Pain Market, 2009

10.3 Pain Drug Sales in Major National Markets

10.3.1 The Pain Drug Market in the US

10.3.2 The Pain Drug Market in Germany

10.3.3 The Pain Drug Market in France

10.3.4 The Pain Drug Market in Japan

10.3.5 The Pain Drug Market in the UK

10.3.6 The Pain Drug Market in Canada

10.3.7 The Pain Drug Market in Spain

10.3.8 The Pain Drug Market in India

10.3.9 The Pain Drug Market in China

11. R&D Pipeline for the Treatment of Pain

11.1 The R&D Pipeline for the Pain Market is Large and Expanding

11.2 The Potential of the Pain Market Has Encouraged R&D

11.3 Innovation Rules for Early-Stage Pipeline Drugs

11.4 Late-Stage Pipeline Products in the Narcotics Sector

11.5 Late-Stage Pipeline Products in the Non-Narcotics Sector

11.6 Late-Stage Pipeline Products in the Anti-Arthritic Sector

11.7 Late-Stage Pipeline Products in the Anti-Migraine Sector

11.8 Late-Stage Pipeline Products in the Anti-Epileptic and Local Anaesthetic Sectors

11.9 The Pain Drug Pipeline Shows Short- and Long-Term Potential

12. Future Therapies

12.1 Cannabinoids and Pain: An Alternative to Opioids?

12.2 Experimentally-Induced Acute Pain

12.3 Post Surgical Acute Pain

12.4 Chronic Pain

12.5 Sativex

12.5.1 European Phase III Trials of Sativex

12.5.2 Sativex Approved for Cancer Pain

12.6 Cannabinoids and Pain: a Lucrative Market?

12.7 The Future of Pain Research

12.8 Advanced Drug Delivery

12.8.1 Delivery of Poorly-Soluble Drugs

12.8.2 Examples of Poorly-Soluble Drugs

13. Interviews with Experts

13.1 Interview with Dr William Schmidt (NorthStar Consulting LLC)

13.1.1 Growth of the Pain Market

13.1.2 New Targets in Pain Management

13.1.3 Unmet Needs in the Pain Market

13.1.4 Regulatory Hurdles in the Post-Vioxx Era

13.1.5 The Future of COX-2 Inhibitors

13.2 Interview with Dr Anastasia Liapi (Astellas Pharma Europe)

13.2.1 Assessing the Commercial Value of Novel Pain Therapies

13.2.2 Hurdles That Face New Launches in the Pain Market

13.2.3 Geographical Differences

14. Conclusions

14.1 The Pain Market is Achieving Sales Growth that Will Last

14.2 The Anti-Epileptics Market

14.3 The Narcotics Market

14.4 The Anti-Arthritic Market

14.5 The Anti-Migraine Market

14.6 Major Success in the Pain Drug Market Has Proved Challenging

14.7 Why Growth of the Pain Relieving Drug Market Will Continue

List of Tables

Table 3.1 The Global Pain Drug Market: Sales Forecast ($m), 2009-2017

Table 3.2 The Global Pain Drug Market: Sales Forecast ($m), 2018-2025

Table 3.3 The Global Pain Drug Market: Sales ($m) and Market Shares (%) Forecasts 2009-2017

Table 3.4 The Global Pain Drug Market: Sales ($m) and Market Shares (%) Forecasts 2018-2025

Table 3.5 Top Ten Products in the Global Pain Treatments Market: Sales ($m), 2009

Table 4.1 The Global Narcotics Market: Sales Forecasts ($m), 2009-2017

Table 4.2 The Global Narcotics Market: Sales Forecasts ($m), 2018-2025

Table 5.1 The Global Non-Narcotics Market: Sales Forecasts ($m), 2009-2017

Table 5.2 The Global Non-Narcotics Market: Sales Forecasts ($m), 2018-2025

Table 6.1 The Global Anti-Arthritic Market: Sales Forecasts ($m), 2009-2017

Table 6.2 The Global Anti-Arthritic Market: Sales Forecasts ($m), 2018-2025

Table 7.1 The Global Anti-Migraine Market: Sales Forecasts ($m), 2009-2017

Table 7.2 The Global Anti-Migraine Market: Sales Forecasts ($m), 2018-2025

Table 8.1 The Global Anti-Epileptics Market: Sales Forecasts ($m), 2009-2017

Table 8.2 The Global Anti-Epileptics Market: Sales Forecasts ($m), 2018-2025

Table 8.3 The Global Local Anaesthetic Market: Sales Forecasts ($m), 2009-2017

Table 8.4 The Global Local Anaesthetic Market: Sales Forecasts ($m), 2018-2025

Table 9.1 SWOT Chart for the Global Pain Drug Market, 2010

Table 10.1 Global Pain Market Revenues ($m) and Shares (%) by Region, 2009

Table 10.2 Countries Leading the Pain Drug Market ($m), 2009

Table 10.3 Pain Market Sales Forecasts for the Leading Seven Countries ($m), 2009-2017

Table 10.4 Pain Market Sales Forecasts for the Leading Seven Countries ($m), 2018-2025

Table 10.5 Seven Major Country Market Shares (%), 2009, 2015 & 2025

Table 11.1 Late-Stage Narcotic Pipeline Agents, 2010

Table 11.2 Late-Stage Narcotic Pipeline Agents, 2010 (Continued)

Table 11.3 Late-Stage Non-Narcotic Pipeline Agents, 2010

Table 11.4 Late-Stage Non-Narcotic Pipeline Agents, 2010 (Continued)

Table 11.5 Late-Stage Anti-Arthritic Pipeline Agents, 2010

Table 11.6 Late-Stage Anti-Migraine Pipeline Agents, 2010

Table 11.7 Late-Stage Anti-Epileptic Pipeline Agents, 2010

Table 11.8 Late-Stage Local Anaesthetic Pipeline Agents, 2010

List of Figures

Figure 3.1 The Global Pain Drug Market: Sales Forecast ($m), 2010-2025

Figure 3.2 Leading Pain Market Segments: Sales Forecasts ($m), 2010-2025

Figure 3.3 Leading Pain Market Segments: Sales ($m) & Market Shares (%), 2009, 2015, 2010 & 2015

Figure 3.4 Leading Pain Markets: Market Shares (%), 2009

Figure 3.5 Leading Pain Markets' Market Shares (%), 2025

Figure 4.1 The Global Narcotics Market: Sales Forecast ($m), 2010-2025

Figure 4.2 Oxycontin Sales Forecast ($m), 2010-2025

Figure 4.3 Duragesic Sales Forecast ($m), 2010-2025

Figure 4.4 Fentanyl Myla Sales Forecast ($m), 2010-2025

Figure 4.5 Actiq Sales Forecast ($m), 2010-2025

Figure 4.6 Other Products: Sales Forecast ($m), 2010-2025

Figure 5.1 The Global Non-Narcotics Market: Sales Forecast ($m), 2010-2025

Figure 5.2 Efferalgan Sales Forecast ($m), 2010-2025

Figure 5.3 Tylenol Sales Forecast ($m), 2010-2025

Figure 5.4 Doliprane Sales Forecast ($m), 2010-2025

Figure 5.5 Advil Sales Forecast ($m), 2010-2025

Figure 5.6 Aspirin Bayer Sales Forecast ($m), 2010-2025

Figure 5.7 Others Agents: Sales Forecast ($m), 2010-2025

Figure 6.1 The Global Anti-Arthritic Market: Sales Forecast ($m), 2010-2025

Figure 6.2 Celebrex: Sales Forecast ($m), 2010-2025

Figure 6.3 Voltaren: Sales Forecast ($m), 2010-2025

Figure 6.4 Arcoxia: Sales Forecast ($m), 2010-2025

Figure 6.5 Loxonin: Sales Forecast ($m), 2010-2025

Figure 6.6 Mobic: Sales Forecast ($m), 2010-2025

Figure 6.7 Others Agents: Sales Forecast ($m), 2010-2025

Figure 7.1 The Global Anti-Migraine Market: Sales Forecast ($m), 2010-2025

Figure 7.2 Imitrex/Imigran Sales Forecast ($m), 2010-2025

Figure 7.3 Maxalt Sales Forecast ($m), 2010-2025

Figure 7.4 Zomig Sales Forecast ($m), 2010-2025

Figure 7.5 Relpax Sales Forecast ($m), 2010-2025

Figure 7.6 Other Agents: Sales Forecast ($m), 2010-2025

Figure 8.1 Global Anti-Epileptic Market: Sales Forecast ($m), 2010-2025

Figure 8.2 Lyrica Sales Forecast ($m), 2010-2025

Figure 8.3 Topamax Sales Forecast ($m), 2010-2025

Figure 8.4 Others Agents: Sales Forecast ($m), 2010-2025

Figure 8.5 Global Local Anaesthetic Sales Forecast ($m), 2010-2025

Figure 8.6 Lidoderm Sales Forecast ($m), 2010-2025

Figure 8.7 Other Agents: Sales Forecast ($m), 2010-2025

Figure 10.1 Global Pain Market Shares (%) by Region, 2009

Figure 10.2 Countries Leading the Global Pain Market ($m), 2009

Figure 10.3 US, Germany and Other Countries: Sales Forecasts ($m), 2010-2025

Figure 10.4 European, Canadian and Japanese Sales Forecasts ($m), 2010-2025

Figure 10.5 Global Pain Market Shares (%) by Country, 2009

Figure 10.6 Global Pain Market Shares (%) by Country, 2015

Figure 10.7 Global Pain Market Shares (%) by Country, 2025 

Companies Listed

AstraZeneca

Abbott Laboratories

Acura Pharmaceuticals

Alpharma Pharmaceuticals

Alza Corporation

Almirall

Anesta Corporation

Applied Pharma Research

Archimedes Pharma

Astellas Pharma

Bayer HealthCare Pharmaceuticals

Biovail Corporation

Boehringer Ingelheim

Bristol Myers Squibb

Cephalon

Cipher Pharmaceuticals

CyDex Pharmaceuticals

Daiichi Sankyo

Dr. Reddy's Laboratories

DURECT Corporation

Endo Laboratories

Epicept Corporation

Ethypharm

Eurand Pharmaceuticals

Genentech

Gruenenthal

GlaxoSmithKline

GW Pharmaceuticals

Health Canada

Hisamitsu Pharmaceutical

Horizon Therapeutics

International Association for the Study of Pain (IASP)

Ikano Therapeutics

Janssen Pharmaceutical

Javelin Pharmaceuticals

Johns Hopkins University

Johnson & Johnson

King Pharmaceuticals

Kowa Pharmaceuticals

Kyorin Pharmaceutical

Labopharm

Lundbeck Pharmaceuticals

MAP Pharmaceuticals

Meda Pharmaceuticals

Merck & Co.

Mylan Pharmaceuticals

Napp Pharmaceutical Group

National Institutes of Health (NIH)

NorthStar Consulting LLC

Novartis

Ono Pharmaceutical Company

Pacira Pharmaceuticals

Pain Therapeutics

Plethora Solutions

PLx Pharma

Pozen Pharmaceuticals

Purdue Pharma

QRxPharma

Ranbaxy Laboratories

Ratiopharm

Recordati Pharmaceuticals

Roxro Pharma

Sanofi-Aventis

Shionogi Pharma

SK Corporation

SkyePharma

STADA Pharmaceuticals

Symbollon Pharmaceuticals

Teva Pharmaceutical Industries

UCB Pharma

US Society for Neuroscience

Valeant Pharmaceuticals

WEX Pharmaceuticals

Winston Pharmaceuticals

World Health Organisation (WHO)

Wyeth Pharmaceuticals

ZARS Pharma

To order this report:

Drug and Medication Industry: Global Pain Relieving Drug Market Analysis 2010-2025

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Reportlinker Adds The Outlook for Pharmaceuticals in Western Europe
2. Reportlinker Adds Atherosclerosis Or Coronary Artery Disease (CAD) - Drug Pipeline Analysis and Market Forecasts to 2016
3. Reportlinker Adds U.S. Market for Hearing Aids and Audiology Devices 2010 (Includes Audiologist Survey)
4. Reportlinker Adds Atrial Fibrillation - Drug Pipeline Analysis and Market Forecasts to 2016
5. Reportlinker Adds World Wound Management Products
6. Reportlinker Adds Negative Pressure Wound Therapy (NPWT) Pipeline Technology and Market Forecasts to 2016
7. Reportlinker Adds Surgical and Medical Instrument Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition]
8. Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015
9. Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015
10. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
11. Reportlinker Adds Top Ten Worlds Leading Orthopedics Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... , February 9, 2016 ... a collaboration with 10x Genomics to develop and ... biology and bioinformatics. --> QGEN ; ... with 10x Genomics to develop and promote comprehensive ... bioinformatics. --> QIAGEN N.V. (NASDAQ: ...
(Date:2/9/2016)... 9, 2016 Amarantus BioScience Holdings, ... developing products for Regenerative Medicine, Neurology and Orphan Diseases, ... company at Source Capital Group,s 2016 Disruptive Growth & ... in New York City . The ... 2016 at 12:30 pm by Gerald E. Commissiong ...
(Date:2/9/2016)... 2016 The leader in accelerated orthodontics, OrthoAccel ... is the recipient of the 2015 Townie Choice Award ... II medical device that speeds up orthodontic tooth movement ... often associated with treatment, AcceleDent was selected by orthodontists ... Orthotown survey of the most reliable and ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... 08, 2016 , ... Brenton Engineering , powered by ... flow wrapped products at WestPack 2015, February 9-11, in Anaheim, California. This new ... semi-automatic or fully-automatic case packing with a small footprint, rugged, highly flexible, and ...
(Date:2/8/2016)... ... February 08, 2016 , ... Tingley Rubber ... Canada to provide its range of unique and advantaged protective solutions to ... that will provide bilingual customer service and marketing support. A new distribution center ...
(Date:2/8/2016)... ... February 08, 2016 , ... The Bell Agency, a ... latest beneficiary of their ongoing community enrichment program. The current campaign fundraises for ... Donations are now being accepted at: http://www.angelsanddoves.com/donate.html . , Angels & Doves ...
(Date:2/8/2016)... San Francisco, CA (PRWEB) , ... February 08, 2016 , ... ... helped raise $792,000 to help combat pancreatic cancer. , Gary D. Radine, who recently ... who also was the American Cancer Society’s 2015 CEO of the Year , ...
(Date:2/8/2016)... ... , ... Remember the old saying “rub some dirt on it”? Perhaps you ... “Calcium Bentonite Clay” the health benefits of integrating clay into a daily diet are ... A former motivational speaker, Perry A~ has since dedicated her life to learning about ...
Breaking Medicine News(10 mins):